GEN Exclusives

More »

GEN News Highlights

More »
Nov 17, 2006

Neuro-Hitech Purchases Q-RNA for over $11M

  • Neuro-Hitech entered into a definitive merger agreement to acquire Q-RNA. Currently, Q-RNA is developing a series of novel compounds that target beta amyloid (A-beta) and are designed to halt or reverse Alzheimer's disease caused by A-beta. In addition, Q-RNA is developing a series of novel compounds for epilepsy.

    Upon the closing of the merger, L. William McIntosh, president and CEO of Q-RNA, will join Neuro-Hitech's as COO. Neuro-Hitech will also employ Q-RNA's discovery and development medical team.

    The merger consideration will consist of an aggregate of 1,800,000 shares of Neuro-Hitech common stock, warrants to purchase up to 700,000 shares of Neuro-Hitech common stock at an exercise price of $13 per share, and warrants to purchase up to 700,000 shares of Neuro-Hitech common stock at an exercise price of $18 per share.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?